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Summary: Biological processes which inight explain the association of pteridine excretion with proliferation are still
unknown. Difficulties in the analysis and the determination of naturally occurring pteridines are described. The best
quantitative estimations were achieved when measurement of non-reduced forms was attempted. The performance
characteristics of such a method for neppterin by high performance liquid chromatography on reversed phase are
given.
Enhanced proliferation and dedifferentiation in cell cultures and organisms is paralleled by excretion of unconjugated
pteridines into the medium or urine.
Urinary neopterin in healthy subjects and in patients with benign diseases was only significantly raised in patients
with viral diseases.
Howevei, an elevation of urmary neopterin occurred in a wide variety of malignant diseases. In haematologic
neoplasias correlatipns of neopterin values to clinicäl features, to tumour staging, and to laboratory data were appar-
ent. The clinicäl Utility of neopterin measurement was also demonstrated in patients with gynaecologic tumours,
particularly in patients with ovarian carcinoma. In both homogenepus patient groups the neopterin assay may
provide an additional aid for prognosis and for monitoring therapy. Comparison of the neopterin assay with already
established tumour marker substances at least revealed no inferiority in sensitivity. The present results justify exten-
sive investigations in prder to eväluate further the clinicäl applicäbility of the neopterin assay.
Pteridine in der Diagnostik von Neoplasien
Zusammenfassung: Die biologischen Funktionen, die die Korrelation der Pteridinausscheidung mit der Proliferation
erklären können, sind bis jetzt noch unbekannt.
Die analytischen Schwierigkeiten und die Bestimmungsmethoden natürlich Vorkommender Pteridine sind beschrieben.
Die quantitative Bestimmung gelingt am besten, wenn nur die Messung der nicht reduzierten Formen angestrebt
wird. Die Zuverlässigkeitskriterien einer solchen HPLC-Methode für Neopterin an reversed phase sind angegeben.
Bei Untersuchung von gesunden Personen und von Patienten mit benignen Erkrankungen wurden nur bei Patienten
mit vitalen Infekten signifikant erhöhte Neopterinwerte beobachtet. Dagegen kommen erhöhte Neopterinwerte bei
vielen malignen Erkrankungen vor. Bei hämatologischen Neoplasien wurden Korrelationen der Neopterinausschei-
dung zu klinischen Parametern, zur Stadieneinteilung und zu änderen Laborkenngrößen aufgefunden. Die klinische
Brauchbarkeit der Neopterinbestimmung wurde ebenfalls bei Patienten mit gynäkologischen Tumoren gezeigt. Bei
beiden homogenen Patientengruppen'sollte die Neopterinbestimmung im Harn zusätzliche Vorteile zur Prognose
und Verlaufskontrolle bringen. Ein Vergleich der Neopterinbestimmung mit anerkannten Jumormarkern zeigt, daß
sie mindestens gleich empfindlich ist wie diese. Die vorliegenden Resultate rechtfertigen ausführliche Untersuchungen
zur weiteren klinischen Erforschung der diagnostischen Möglichkeiten der Neopterinbestimmung.
Introduction ^^
 is probably because the pteridines have been in-
Biological functions of unconjugated pteridines vestigated only recently and only by a few laboratories.
In contrast to the field of purines, the biological func- The reason for this comparatively late research into their
tions of most unconjugated pteridines are unknown, biological role lies certainly in analytical difficulties. In
despite their common occurrence in various organisms. some cases the problems of Isolation and characterization
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are caused by the low concentrations of pteridines in
biological samples; they are generally present only in
trace amounts (1,2). An exception is the relatively high
concentrations which are found in the wings ofPteridae
butterflies. Other problems result from chemical ab-
normalities such äs photolability, uncpmmon solubility
and lack of melting points.
An excellent review of pteridine chemistry up to 1963
is given by Pfleiderer (2). Interesting and more recent
aspects of analysis were described in the reports of the
pteridines symposia held at Konstanz in 1973 (3) and
at La Jolla, California, in 1978 (4), (5-12).
Pteridines are found äs pigments in the skin and eyes of
insects, amphibians and fish. The essential metabolic
roles of unconjugated pteridines which were known or
had been proposed till 1982 are summarized in a review
by Rembold (1). Today, the best established function
is that of 5,6,7,8-tetrahydrobiopterin which serves äs
cofactor for a set of enzymes which hydroxylate phenyl·
alanine, tyrosine and tryptophan using molecular oxygen
(13, 14). A siniilar enzyme catalyses the conversion of
glyceryl ethers to carboxylic acids and glycerol (15).
Participation of pteridines in the photosynthetic elec-
tron transport of photosynthetic bacteria and chloro-
plasts of higher plants has been proposed by several
authors (16,17). The possibility of a regulatory func-
tion of pteridines in melatonin biosynthesis (18) and of
an interactiori between pteridines and DNA (19)
requires more detailed research.
Biosynthesis of the pteridine ring
Unconjugated pteridines are synthesized de novo by
mammals and by other higher animals äs reported by
Kraut et al. (20) and byPabst &Rembold(2l). As
shown in figure l, during biosynthesis the pteridine
ring arises from the purine ring. GTP (guanosine tri-
phosphate) is converted enzymatically to dihydro-
neopterin triphosphate. The äbility of guanine com-
pounds to serve äs precursors of pteridines was in-
vestigated in larvae ofDrosophila melanögaster by
Brenner-Hohach ScLeuthärdt (22) and in butterfly-
species by Weygand et al. (23) and by Watt (24). Jones
& Brown presented direct evidence that dihydro··
neopterin is formed enzymatically mEscherichia coli
from GTP (25). The same synthetic scheme is also
established in Comamönassp. (26), in the büllfrog,
Rana catesbeiana (27), in Drosophila melanögaster (28),
in the Chinese hamster and the Syrian golden hamster
(29).
Biological conversion and degrädation
of pteridines
As shown in a reaction scheme by Rembold (30) enzyma^
tic or nön-enzymatic modification such äs cleavage of
the side chain, deamination or pxidation of 7,841-
hydroneopterin could give rise to naturally occurring
pterins such äs monapteriri, biopterin, sepiapterin,
xanthopterin, isoxanthopterin, pterin and lümäziries.
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Fig. 1. Biosynthesis öf jD^erythro^rieopterin from GTP.
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These are the same reactions that occur in the degrada-
tion and thus these pteridines are found äs terminal
metabolites in culture media of cells and in urine. The
different excretion products depend on the presence or
absence of specific enzymes. For example, the occur-
rence of lumazines requires the presence of a pterin
deaminase. For most organisms the pteridines represent
true terminal catabolites (1).
Analy tical Methods for Unconjugated Pteridines
The diagnostic significance of tumour markers is
strongly influenced by the method available for their
measurement. As the pteridines occur in extremely
small amounts in biological materials the analytical
method has to be sensitive, specific and accuiate. For
clinical laboratory use the practicability of the assay
has to be taken into consideration.
A sensitive growth assay using the microorganism
Crithidia fasciculata has been reported by Guttman (31).
This assay, which is applicable for Zr-biopterin and its
reduced forms has been most frequently used, but it is
very tedious and time consuming.
In newer methods pteridines are detected by their
native fluorescence which generally gives a specific and
sensitive determination.
Determination of pteridines by paper chromatography
(32) or thin layer chromatography (33, 34) does not
enable sufficiently accurate quantification. High voltage
electrophoretic Separation of pteridines (34—36)
presents similar problems. The determination of pteridi-
nes using isolation techniques on ion exchange materials
in a two Step Separation has been widely applied (37,
38) and adapted for biological fluids. Advances in
liquid chromatography have led to the development of
high performance liquid Chromatographie (HPLC)
techniques.
Pteridines have been separated by cation exchange
HPLC techniques by different laboratories (39-42).
Although sensitivity and specificity is Increased com-
pared to the methods cited above, the practicability is
diminished by a necessary preliminary purification of
the biological material. Practicability and accuracy can
be optimized to a greät extent by HPLC-anälysis on
reversed phäse. Such assays for the estimation of un-
conjugated pteridiries have been described by several
laboratories (42-46), För example the HPLC method
on reversed phäse was optimized for the urinary
neopterin measurement (47): Rapid Separation of urine
constituents was achieved by an isocratic solvent System
on a 10 reversed phäse C18 column following a
sample preparation through C18 cartridges. Subsequent
to elution of neopterin a flow and composition gradient
was established in Order to accelerate column purifica-
tion.
Neopterin has been monitored using a spectral fluores-
cence detector. In order to reduce the effect of physio-
logical variations in urine concentration the neopterin
concentration was related to that of creatinine; for this
reason it was advantageous that creatinine could be
estimated simultaneously with a spectral absorption
detector (48). As shown in table l, this method provides
good performance characteristics and is easy to handle.
The assay was modified by using a guard column (49),
thus enabling automation for routine clinical laboratory
use. A gas chromatography-mass fragmentography
method (50) seems particularly suited äs a reference
method. As it is difficult to analyse many samples during
one day this accurate assay is not useful for routine
laboratories. A radioimmunoassay for biopterin (51)
represents an attractive alternative if the HPLC equip-
ment is not already at hand. Thus an i-erythro-biopterin
specific assay is applicable to body fluids and tissues.
Tab. 1. Performance characteristics of the urinary neopterin
determination by HPLC on reversed phäse. Neopterin
levels were measured simultaneously with creatinine
levels and relate d t o these. * )
*) Data from Hausen et al. (47).
Lineaiity
Sensitivity
Precision
Accuracy
Specificity
from 200 nmol/1 neopterin to at least 40 /
regression equation: y = 1.006 - 2.94;
r = 0.9999
120 nmol/1 neopterin or 120 fmol/injection at a
peak/noise ratio of 5:1
Sample
n
CV%
within run
1 2
20
6.5
24
3.8
3
24
3.8
between day
1 2
15
7.4
15
2.8
3
15
7.1
mean valüe of 99.3% recovery with 6 spiked
urinary samples.
tested through fluorescence spectra for Standard
and eluted urinary sample following HPLC
Separation.
Practicabitity anajysis of one sample requires 20 minutes;
measurement of 60 samples within 24 hours;
low cost pf reagents.
Measurement of the total amount of reduced and
oxidized pteridines after conversion to the fully oxidized
state has also been reported (41, 52). Since the use of
test substances showed a recovery of 80—90%, quantifica-
tion of reduced forms using this technique does not yet
seem possible with the desired precision and accuracy.
The optimized analytical techniques have enabled
research into the relationship between pteridines excre-
tion and biological parameters. The present investiga-
tions were undertaken to study the behaviour of
pteridine excretion in cancer patients.
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Excretion of Pteridines from Cells, Plants and Animals
Pteridine excretion äs indicator of cell
proliferation
Various procaryont and eucaryont organisms excrete
pteridines during the growth phase (53.). E. coli secretes
monapterin in the logarithmic growth phase. At the
switch to the stationary phase the excretion of mona-
pterin experiences a burst, whereas in the stationaiy
phase E. coli hardly releases any pteridines. The slime
mouldPhysarum polycephalwn excretes isoxanthopterin
andAcetabularia mediterranea pterin-6-carboxylic acid
into the medium. In the same manner the rapid growth
ofCalanchoe tubiflora is paralleled by release of iso··
xanthopterin, and the germination of potatoes (Solanum
tuberosum) by excretion of isoxanthopterin and mona-
pterin into the medium.
Pteridine excretion äs indicator of rapid
or malignant proliferation
Association of pteridines with high metabolic activity
in dedifferentiating tissues was indicated by Kokolis &
Ziegler (54) and by Kokolis et al. (55). Elevated con-
centrations of tetrahydrobiopterin were detected in the
skin of Triturus species during larval development and
in the regeneration blastema of the adult newt after tau
amputation. Interestingly, the growth rate of the
regeneration bud was strongly inhibited by injection of
isoxanthopterin after amputation.
Kokolis et al. (56) compared tetrahydrobiopterin levels
in tissues from human squamous cell carcinoma with
levels in tissues from rats. In the tumour samples the
ratio of tetrahydrobiopterin to riboflavin was much
higher than in normal tissue with high metabolic activity.
Furthermore, Kokolis & Ziegler (57) reported that tetra^
hydrobiopterin levels in the blood of tumour-bearing
rats (Ascites AH130 and Guerin T-8 tumours) were
raised compared with those in healthy rats.
Albrecht and coworkers (58) investigated the biopterin
content of several cell lines in human neuroblastoma.
They observed markedly higher biopterin levels in
adrenergic neuroblastoma, glioblastoma and fibroblast-
like cell lines. 6-Hydroxymethyl-pterin was also shown
to be excreted into the medium in large amounts by
cancer cells (59).
Increased excretion of a fluorescent component was
found in the urine of mice beäring .Ehrlich ascites
tumour (35). This metabolite was identified äs 6-hydroxy-
lumazine which originates during analysis from 7,8-di-
hydro-6-hydroxylumazine (36). The urinary excretion
of this pteridine related to indoxylsutfate (excreted at a
constant rate in mice) was determiried äs 0.65 ± 0.21
(mean ± SD) for 110 healthy mice. In contrast, this
quotient increased to 2.47 ± 1.09 (mean ± SD) for
120 Ehrlich ascites tumour-bearing mice on the fifth
day after tumour transplantation. As shown in figure 2
this quotient üicreases up to the sixth day and then
falls; there is a similar increase in the number of tumour
cells. In these animals, tumour proliferation is paralleled
by the excretion of 7,8-dihydro-6^hydroxylumazme,
which thus acts äs an index of tumour growth.
Tumour
transplantation
l
-2 6
Hd] 10 17
Fig. 2. Urinary levels of 7,8-dihydro-6-hydrpxylumazine in rela-
tion to indoxylsulfate (arbitrary fluorescence units) fol-
lowing transplantation of Ehrlich ascites tumour in mice.
Each point corresponds to the mean value from 12 mice.
Excretion of Pteridines in Healthy Subjects
A pterin present in pupae of bees was identified äs
2^amino-4-hydroxy-6(P-erytitu:p-l ,2,3-trihydroxy-
propyl)-ptendine byRemböld & Buschmann (60), who
called i t neopterin.
Sakurai & Goto (38) isolated neopterin from human
ürine. Quantitative estimation of urinary neopterin arid
biopterin was first performed by Fukushima &Shiota
on 4 healthy persons (61)- Since these results arid those
of Fukushima &Nixon ajid of Fukushima et äl. (52, 62)
(3 healthy subjects each) äre presented in mg pterin
per liter urine, they äre riot comparable with the data
of other authors. The same is true of the urinary biop-
terin levels obtained by Leeming and coworkers (63)
using the Crithidia fasciculata assay on 60 healthy
persons. The qüanüficätioiis of urinary pteridines
related to creatinine, which have so far been published,
äre summarized in table 2. With one exception, rrteas-
urement of the total reduced and nonreduced forms
was attempted. Oxidation of pteridines by the available
methods is not quantitative (44) and was at first not
reproducible (47, 52,62). These methodological diffi-
culties explain conflicting results obtained using these
methods. However, the new data (42,64^ 67,68)
compare well.
A reeent investigation (69) with 417 healthy individuals
(208 male, 209 female) showed that at all ages the men
had significantly lower mean values than the women
(p < 0.01). In addition, a correlation between the
J. Cün. Chem. Glin. Bipchem. / Vol. 20,1982 / No. 9
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Tab. 2. Comparison of normal values of urinary pteridines obtained from different authors.
a) the total of reduced and non reduced pteridines was determined following oxidation
b) the native neopterin was determined. Pteridine levels in μπιοί pteridine per mol creatinine
References
a) R thler & Karobath (50)
a) Niederwieser et al. (64)
a) Stea et al. (65)
a) Rokos et al. (66)
a)Z>Ao/i<ffetal. (42)
a)/>Aomifetal. (67)
a)7Vjg fsw etai. (51)
a) Nagatsu et al. (68)
b) W chter et &L (43)
b) Hausen et zl (49)
b) Hausen et 3l. (47)
Number
of subjects
9
7
20
23
12
55
13
13
62 <5
439
208 6
2099
60 children
Pterin Neopterin
6-carboxylic-
acid
223 ± 74
280
27 ± 3 794 ± 34
221 ± 81
280 ± 50
306 ± 91
125 ±52
152 ±52
115 ±36
140 ± 40
163 ± 65
Biopterin
457 ± 165
720
1173 ± 54
283 ± 101
709 ± 162
674 ±188
893 ± 96
739 ± 77
Xanthopterin Isoxantho^
pterin
679 ±49 120 ±25
229 ± 73
neopterin/creatinine ratio and age was demonstrated.
Children have notably higher urinary mean neopterin/
creatinine values (47,67). This relationship may result
to some extent from the distinct Variation of urinary
creatinine levels with sex and age.
Since the most useful application of tumour markers at
the present time is the monitoring of treatment, the
oscillation of the neopterin excretion over a longer time
period is of interest. The urinary neopterin levels were
determined daily over a one-month period in 4 normal
individuals (47). The individual v riance coincided with
the r nge found to be typical for people of the same sex
and age.
In order to assess neoplasias the upper normal limits of
urinary pteridines must be statedL Rokos and coworkers
(45) considered values of neopterin ab ve 447 μπιοΐ/τηοΐ
creatinine ΐο be abnormal. H wever, this limit which was
based on the estimation of neopterin and biopterin
following an oxidation Step prior to analysis by HPLC,
did not take into account the sex- and age-dependent
variations of urinary neopterin levels (49,67,69).
Recommended upper levels of normal excretion, which
do take into account the sex- and age-dependence of
urinary neopterm have recently been stated (49,69),
Table 3 shows the mean and median values and the upper
confidence limits for eaeh sex and age group. These
limits, calculated according toLieberni nn (70), include
with 95% probability 97.5% of healthy subjects, thus
enabling the accurate Interpretation of results.
Excretion of Pteridines in Patients with Benign Diseases
Measurement of urinary pteridines is of clinical value in
the recognition of variants in phenylketonuria patients
(71,42,64). Tetrahydrobiopterin serves s cofactor of
the monooxygenases phenylalanine-4-hydroxylase,
tyrosine-3-hydroxylase and probably tryptophan-5-
hydroxylase. The classical phenylketonuria is caused by
enzyme deficiency; about 1—3% of the phenylketonuria
patients suffer from tetrahydrobiopterin deficiency due
to molecular defects grouped in dihydropteridine reduct-
ase deficiency and dihydrobiopterin synthetase deficiency.
Since different deficiencies require specific treatment
early diagnosis is important. Determination of urinary
pteridines is eonsidered a useful tool for classification
of phenylketonuria patients. High levels of urinary
dihydroxanthopterin were found in classical phenyl-
ketonuria patients and in variants (34,72, 73). In recent
reports increased urinary levels of biopterin derivates in
dihydropteridine reductase deficiency (74,64), low
serum levels of tetrahydrobiopterin and high urinary .
levels of neopterin in 7,8^dihydrobiopterin synthetase
Tab. 3. Normal urinary neopterin levels (μπιοί neopterin per mol
creatinine) and upper confidence limits for different sex
and age groups obtained from 417 healthy individuals.*)
*) From Hausen et al. (49)
**) Upper limits tested according to Liebermann (70)
containjng with 95% probability 97.5% of healthy
subjects.
Age
18-25
26-35
36-45
46-55
56-65
>65
18-25
26-35
36-45
4$ -55
56-65
>65
Sex
d
<5
6
6
6
d
9
9
9
9
9
9
Noof
subjects
42
29
41
32
31
33
55
28
31
28
26
41
x ± S D
123 ±30
101 ± 33
109 ± 28
105 ± 36
119 ±39
133 ±38
128 ±33
124 ± 33
140 ± 39
147 ± 32
156 ± 35
151 ±40
Limit of
tolerance**)
195
182
176
197
218
229
208
209
239
229
249
251
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deficiency (75,64) were demonstrated. These data
were confirmed by Dhondt and coworkers (67) using
age-paired comparisons.
Significantly (p < 0.0001) raised neopterin levels occur
in patients with viral diseases (43,66). Urinary neopterin
levels were affected moderately by benign cell renewal
(76). In 5 patients who had undergone surgery (laparo-
tomy) the highest neopterin excretion was observed
between the third and the sixth day. On the day of the
highest level, the mean neopterin value ± SD in
neopterin per mol creatinine was 233 ± 40. In figure 3 a
typical change in urinary neopterin levels following
laparotomy due to cholelithiasis is depicted.
20
Fig. 3. Urinary neopterin levels following laparotomy due to
cholelithiasis. The ränge below the upper limit for female
individuals, age > 65 years, is hatched.
Slightly increased neopterin levels were observed in
patients with hyper-regenerative bone marrow (49). In
patients with haemolytic anaemia the mean neopterin
value was only a little higher than that of healthy con-
trols. In 5 patients with renal insufficiency coupled with
renal anaemia, the mean urinary neopterin level increased
nearly to the upper normal limit (45). In 9 patients
with renal insufficiency and in 7 patients with psoriasis,
mean values above the normal limit were found (66).
Excretion of Pteridines in Patients with Malignant
Diseases
Studies in advanced neoplasias of different sites
Early reports on patients with malignancy showed a
raised excretion of fluorescent urinary components,
which were very probably pteridines (77,78). A pterin
excreted by patients with cancer and by malignant cells
in tissue culture media was originally tentatively
identified äs pterin-6-aldehyde (33), but was later
identified äs 6-hydroxymethylpterin (59). A con-
temporary investigation using the same thin layer
Chromatographie assay System for urine samples showed
clearly that the mere presence of pterin-6-aldehyde
is not diagnostic for cancer (79). ; r
A clinical study by Wächter and coworkers (43) fiist
revealed raised urinary neopterin levels in cancer
patients. The mean neopterin value of 40 patients with
various malignancies was significantly higher
(p < 0.0001) than that of a control grqup öf 43
healthy subjects. Further däta on neopterin levels in
patients suffering frpm various types of neoplastic
diseases came fiomRokos et al. (50 patients (45); 75
patients (66)) and gave similar results.
More recently Stea et al. (65) cqnfirmed these eiihänced
urinary mean neopterin levels in 20 patients with ad-
vanced cancer, of which the majo^ty had recüreent
metastätic disease. In addition, these authors examined
the excretion of seven unconjugated, pteridines and
showed a significant inerease of mean xanthopterin
and pterin äs well äs a significant decrease of iso-
xanthopterin when cpmpared to a control group of 27
healthy subjects,
Studies in homogeneous groups of neoplasias
The studies reviewed above indicated clearly that urinary
neopterin elevations occur in a wide variety öf malignant
diseases. Therefore, subseqüent investigatiöns shouid be
directed towards more homogeneous groups of neor
plasias. The clinical significance of the neopterin estima-
tion in cancer diagnosis, in the staging of disease and in
monitoring cancer treatment requires detäiled studies.
Urinary neopterin levels and cof relations to clinical
features, to tumour staging and to laboratory data have
been described in haematological neoplasias (49,76).
Results obtained from 216 patients with haematological
neoplasias are shown in table 4. All patients with maligr
nancies in an active state (n = 135) revealed significantly
(p < 0.0005) elevated mean values when compared to
the sex- and agepaired control group. The patients with
multiple myelömä stage I in which the meail value was
raised only moderately and almost eoincided with the
upper normal limit were exceptions. The total frequency
of elevated neopterin levels for patients in an active
state was 114/135 (84%),
On the other band, the inean values of 56 patients with
neoplasias in remission and of 25 patients with benign
haematological diseases were below the upper normal
limit. Only 7/56 (12.5%) of patients witb neoplasias in
remission and 4/25 (16%) of patients with benign
diseases were in the pathological ränge. It is interesting
to nöte that neoplastic pröliferations such äs multiple
m^eloma arid polycythaemiä vera, which represent
prototypes of weU-differentiated tumours, exhibited
only moderately increased mean va&es. to contrast,
J. Clixi. Chem. Cün* Biochem. / Vol. 20,1982 / No. 9
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high mean values were shown in poorly differentiated
chronic lymphoid leukaemia and in non-Hodgkin's
lymphoma occurring in both poorly and well-differentir.
ated forms.
In patients with chronic lymphocytic leukaemia and
with non-ffodgkin's lymphoma the urinary neopterin
levels correlated with the stage of disease (76). The
mean neopterin values in stages I and II were signifi-
cantly raised compared to the control group. The
highest mean values were observed in patients with
stages III and IV and with large tumour burdens.
In patients with chronic leukaemias the urinary neopte-
rin excretion correlated with occürrence of hepato-
splenomegalia and with haematological criterias such
äs serum levels of leukocytes, platelets and haemoglobin.
These data suggest that the urinary neopterin assay can
advantageously supply clinical and laboratory para-
meters to assess the extent, progression and outcome
in haematological neoplasias.
The clinical Utility of the urinary neopterin measure-
ment was improved in patients with gynaecological
tumours (69). There was a significant difference
(p < 0.01) between the mean values of 63 untreated
tumour patients and 96 healthy women compared in
each case to the age-paired group. Table 5 shows the
clinical significance of the urinary neopterin estimation.
Of patients examined at the onset of therapy, 41/63
(65%) exhibited neopterin levels above the upper nor-
mal limit.
Tab. 4. Urinary neopterin levels ( neopterin per mol creati-
nine) and frequency of values exceeding the upper limits
of normal in patients with haematological neoplasias,*)
haemolytic anaemia and benign paraproteinaemia.
*) Data from Hausen et al. (49)
**) Upper limits tested according to Liebermann (70)
containing with 95 % probability 97.5% of healthy
subjects.
Diagnosis
Haemolytic
anaemia
Benign para-
proteinaemia
Polycythaemia
vera
Multiple myelöma,
stage I
Multiple myelöma,
stage II, III
Multiple myelöma,
remission
Hodgkin**
lymphoma
ffodgkin's
lymphoma,
remission
Aoute leukaemia,
remission
Chronic myelpcytic
leukaemia
Chronic
lymphocytic
leukaemia
Non-Hodgkinys
lymphoma
Kon-Hodgkin's
lymphoma,
remission
No.
of
sub-
jects
16
9
12
7
20
7
16
24
12
21
26
33
13
x ± SD
178 ± 80
167 ± 58
363 ± 183
249 ± 183
384 ± 183
147 ± 39
347 ± 130
231 ± 96
145 ± 63 '
552 ±317
612 ±266
710 ±440
193± 70
Above
the
upper
lim-
it**)
3
1
9
2
14
0
14
5
- 1
20
25
30
1
% in the
pathp-
logical
ränge
19
11
75
29
70
0
88
21
8
95
96
91
8
Tab. 5. Distribution of urinary neopterin levels in patients with
gynaecological tumours prior to beginning of therapy
and in follow up treatment.*
*) Data from Dichter et al. (69)
**) Upper limits tested according to Liebermann (70)
containing with 95% probability 90% of healthy
women.
Prior Follow-up treatment
to beginning
of therapy
No Above No Corre- %
of the of spond- Corre-
sub- upper sub- ence to spond-
jects lim- jects clinical ence
it**) and
X-ray
findings
Ovarian cancer 8 7 26 21 81
Cervicai cancer 39 23 36 27 75
Endometrial 13 9 10 5 50
cancer
Cancer 3 2
of the vulva
Total 63 41 72 53 74
(65%)
It is noticeable that in follow-up treatment in patients
with gynaecological malignancies the neopterin assay
provides even better results. In 53/72 (74%) patients the
clinical and X^ray findings corresponded well with the
urinary neopterin levels.
Both reports (49, 69) suggest a potential usefulness of
the urinary neopterin measurement in the assessment of
haematologic neoplasias and of gynaecologic tumours.
A clinical applicability of the neopterin assay in these
malignancies appears likely.
Comparison of the urinary neopterin assay
with other tumour markers
The initial burst of enthusiasm in the field of tumour
markers has greatly disappeared during the past several
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years, and this field has been the subject of considerable
questioning (80, 81). Problems involved in this area may
partly be caused by methodic difficulties which lead to
inconsistent results. Often somewhat low upper normal
limits were stated no doubt producing high frequency
of elevated levels in carcinoma patients and also in
patients with benign diseases and in healthy subjects.
Thus, the lack of true cancer specificity is seen äs the
main drawback of the known tumour marker substances.
To date, more rational studies have been undertaken to
evaluate the role of tumour markers. Extensive clinical
investigations have revealed that the value of tumour
markers does not necessarily lie in their use for cancer
screening and for early diagnosis (82, 83, 84); a con-
siderable amount of pertinent data indicate that tumour
markers help in prognosis and in monitoring cancer
treatment äs an adjunctive tool for the clinical and physi-
cal examination (85, 86, 87).
Urinary neopterin seems to be a sensitive marker com-
pared with the best established biochemical markers, such
äs polyamines for haematologic (96) and carcino-
embryonic antigen for gynaecologic tumours (97). Such
a comparison would require measurement of all three
markers concurrently in a study of the same patients.
At present, only results of different authors are avail-
able. The problems inherent when comparing such
results are the clinical examination and the considerable
difference of the upper normal limits used. This varia^
bility in the upper normal limits seems to limit the use-
fulness of the CEA assay äs a tumour marker at the
present time. For the reasons stated, the occurrence of
elevated levels of the three markers shown in table 6
has to be interpreted with caution.
However, in table 6 there is some evidence that the
sensitivity of the urinary neopterin assay is at least com-
parable with that of polyamine sampling for haema-
tologic neoplasias. The polyamines äs tumour associated
markers require determination of three components
(putrescine, spermidine and spetminer). Therefore we
believe that the neopterin technique is superior tp the
polyamines method with respect to rapidity arid
applicability to routine analysis. Apart fröm this
methodic aspect, the biological mechanism involved in
the excretioii of neopterin differs distinctly frpm that
of polyamines. No statistically significant difference of
neopterin levels between treated and untreäted patients
was observed (49). In contrast, a correlatiori between
increase of spermine arid spermidihe with cell death
due to treatment has been reported (98).
In table 6, the neopterin assay is compared to the CEA
assay äs the best biochemical marker for carcinomas of
the female genital träct at the present time. tt has to be
npted that the neopterin estimation i§ not inferior with
respect to sensitivity. Most diagnostic difficulties of
carcinomas in the female genital tract are encöuntered
in carcinoma of the qvary. In contrast to the CEA resülts
the incidence of neopterin elevations was found to be
particülarly high for this type of carcinoma. Therefore,
the determination of urinary neopterin levels in additiöri
to the X-ray and clinical fmdings would be öf benifit for
the clinician in the manägement öf ovarian cancer.
At present, pfospective studies on the clinical applica-
tions of neopterin levels have -still not been performed.
We emphasize that neopterin elevations associated
with tumours were first described in 1979 (43). CEA
was pröposed äs a tümouf marker by Gold & Freedman
in 1965 (99) and polyamines by'Rüssel in 1971 (100).
Tab. 6. Comparison of different tumour markers in patients with haematological neoplasias and with tumours of the female genital
tract.
% = incidence of elevated levels in % (n) = number of patients investigated
Diagnosis
Neopterin CEA
(n) Authors (n) Authors
Polyamines
(n) Authors
Polycythaemia vera
Multiple myeloma
Hodgkin's lymphoma
Non-Hodgkin's lymphoma
Chronic myelocytic
leukaemia
Chronic lymphocytic
leukaemia
75
59
88
91
95
96
12
27
16
33
21
26
(49) 64
(49)
(49)
(49)
(49)
(49)
f 60-100
35 72 (89) j
 55^ 68
78
38 40 (89)
11
11
38
123
(88)
(90)
(90>
'(90)
Carcinoma of ovary
Carcinoma of cervix
Carcinoma
of endometrium
88 8 (69)
59 39 (69)
69 13 (69)
45
21
19
17
40
34
30
43
20
11
53
140
30
40
97
54
88
10
(91)
(92)
(93)
(94)
(91)
(93)
(94)
(95)
(92)
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Since the neopterin assay is still at an early stage of
development its biological role remains open. Results
presented in table 4 and S indicate that high mean
urinary neopterin levels and a high incidence of eleva-
tions occur particularly in undifferentiated neoplasias.
The lowest occurrence of elevated levels obtained in
patients with carcinoma of the cervix appears to reflect
a poor clinical correlation of urinary neopterin levels
in well differentiated solid tumours of epithelial origin.
Current experiments with mixed lymphocyte cultures
(unpublished) explain that the neopterin excretion is
associated with activation of T-lymphocytes. As already
supposed (76) elevated neopterin levels seem to represent
end products of a host response — the cell mediated
immunity — against the tumour. This hypothesis is con-
sistent with the high neopterin levels observed in patients
with viral infection (43) which activates T-lymphocytes.
Conclusions
HPLC on reversed phase enables the determination of
urinary pteridines with satisfactory sensitivity, accuracy
and practicability, äs is necessary for tumour markers in
routine clinical laboratory use.
In this survey, an association was indicated between
enhanced or dedifferentiated proliferation and release
of pteridines into cell culture media or urine. Further,
high pteridine Contents in rapidly growing tissues were
demonstrated.
There are several reports that have confirmed raised
' neopterin levels in patients with malignancies in ad-
vanced disease of various types.
For the clinical Utility of the neopterin assay it is
advantageous that neopterin levels above the upper
normal limit rarely occur in healthy adults or in patients
with benign diseases and occur only in a low percentage
of patients with neoplasias in remission.
The urinary neopterin assay has been tested in detail
for two homogeneous groups of malignancies, namely
haematological and gynaecological neoplasias. Correla-
tions to clinical staging, to well established clinical
features and laboratory data have been shown. Further-
more, it appears that the neopterin determination aids
the monitoring of therapy in cancer patients.
The frequency of urinary neopterin elevations was com-
pared with literature data of polyamines äs markers for
haematologic, and of CEA äs marker for gynaecologic
neoplasias. The'urinary neopterin assay is at least com-
parable to these assays.
In summary, the results of the urinary neopterin measure-
ment are encouraging. Further exploration of the clinical
application should be pursued particülarly in poorly
differentiated neoplasias of non epithelial origin.
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